ISSN 2997-1036
International Journal of Hematology | Vol. 9, No. 3, March 2018 | pp. 17–24
DOI: 10.46882/2018/IJH/000099
Original Article
Title: Immunophenotypic profile and clinical stage stratification of B-cell chronic lymphoproliferative disorders using CD200 and CD43 expression markers
Names of Authors: W. A. Adebayo¹, X. Y. Emeka², Z. Z. Salami³
Authors’ Affiliations: ¹Department of Haematology, University of Ibadan, Ibadan, Nigeria; ²Department of Haematology, University of Calabar Teaching Hospital, Calabar, Nigeria; ³Department of Pathology, Lagos University Teaching Hospital, Lagos, Nigeria
Abstract: Multiparameter flow cytometry immunophenotyping plays a critical role in distinguishing chronic lymphocytic leukemia from other mature B-cell lymphoproliferative variants. This prospective study evaluated the diagnostic performance of incorporating CD200 and CD43 markers into a standard screening protocol for 65 adult patients presenting with persistent absolute lymphocytosis (> 5.0 × 10⁹/L). Lineage restriction was verified via monoclonal light chain patterns. Chronic lymphocytic leukemia was confirmed in 48 patients based on clinical features and Matutes scores, while 17 cases were diagnosed with non-CLL lymphoproliferative disorders. Strong, uniform surface co-expression of CD200 and CD43 was detected in 95.8% (46 of 48) of the chronic lymphocytic leukemia cases. In contrast, all 17 non-CLL variants (including mantle cell lymphoma and marginal zone lymphoma) demonstrated complete absence or dim expression of these markers (P < 0.001). High CD200 density expressions correlated with early Binet clinical stages (Stage A). Incorporating CD200 and CD43 into routine flow screening provides excellent diagnostic accuracy, reducing ambiguous scores and optimizing lineage separation.
Keywords: Chronic lymphocytic leukemia, CD200, CD43, flow cytometry, lymphoproliferative disorders, immunophenotyping
Manuscript Timeline: Received: December 05, 2017; Revised: January 14, 2018; Accepted: February 04, 2018; Published: March 19, 2018